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Introduction. The risk of developing subsequent primary cancers varies from 1% to 18% and it depends on the type 
of first cancer and treatment methods applied. Considering the time of occurrence, multiple primary cancers generally 
fall into two categories: synchronous and metachronous. In breast cancer patients, 10.5% developed multiple primary 
cancers, from which 23.8% had synchronous, 79% had metachronous and the remaining 2.8% had both synchronous 
and metachronous malignancies. In patients with breast cancer, elevated risk is observed especially in the development 
of contralateral breast cancer, endometrial cancer, esophageal cancer, ovarian cancer and thyroid cancer.
Aim. This paper presented the characteristics of breast cancer patients with metachronous primary malignancies in 
relation to the type of metachronous primaries (breast versus non-breast) and to analyse the impact of the type of 
metachronous cancers on survival rate.
Material and methods. Among patients treated for breast cancer between 1963 and 2010, 354 patients (2.1%) developed 
metachronous primary malignancies and these made up 13.8% of all patients with multiple primary cancers. The mean 
age at diagnosis of the first breast cancer was 53 ± 11.5 years; positive family cancer history was noted in 127 patients 
(35.9%). Metachronous malignancies are defined as primaries following the diagnosis of breast cancer in a time interval 
greater than or equal to than 6 months. In our group, the mean time interval between the diagnosis of breast cancer and 
the appearance of metachronous malignancies was 100.9 ± 74.9 months (range: 6–543 months, median: 83 months). 
For comparison of the two groups (patients with second breast vs non-breast cancer) we used the Pearson’s Chi-square 
test for independence (for categorized variables) and variance analysis with Student’s t-test (for continuous variables). 
The survival rate was evaluated with the Kaplan-Meier method, and the log rank test was applied to assess the influ-
ence of some factors on the evaluated results. The significance level at α = 0.05 was adopted for all statistical analyses.
Results. The probability of occurrence of new cancer averaged from 38.1% to 67.8% for 5 and 10 years after diagnosis of 
first breast cancer, respectively. In our group, 380 cases of metachronous carcinomas were noted in 354 analysed patients. 
The most frequent metachronous malignancy was breast cancer (194 cases — 54.8%), which occurred as second (192 
cases) or third (2 cases) cancer. Patients with contralateral breast cancer in comparison to other types of metachronous 
malignancies were significantly (p < 0.05): younger (under 50 years: 56.2% vs 34.4%), premenopausal (69.6% vs 48.8%), 
had a lobular type of first breast cancer (6.7% vs 1.3%), and rarely received tamoxifen (25.3% vs 48.2%). The type of me-
tachronous cancers significantly influenced survival rate: 10-year overall survival rates were 80.1% vs 67.8%, (p = 0.0271).
Conclusions. The risk of occurrence of second malignancies in breast cancer survivors makes early detection of 
metachronous malignancies obligatory because it is an important factor which influences the quality of life in breast 
cancer survivors.
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Introduction
The advances in cancer therapy, early detection and 
supportive care have contributed to the improvement of 
survival rates. About 70% of all cancer patients survive at 
least five years after diagnosis. The number of cancer survi-
vors is growing rapidly, by about 2% each year. Therefore, 
the identification of the subsequent effects of cancer and 
its treatment has become a critical problem due to their 
long-term clinical and physiological importance. One of 
these late events is the diagnosis of a new cancer in cancer 
survivors — a second, third or higher-order primary in some 
cases [1–6].
Published data indicate that the risk of developing sub-
sequent primary cancers varies from 1% to 18%, and this 
depends on the type of first cancer and used treatment 
methods [3, 6–11].
Causal mechanisms of multiple primary cancer devel-
opment include genetic predispositions, environmental 
exposures, lifestyle factors as well as late sequelae of cancer 
treatment (cytotoxic, radiation or hormonal therapies), its 
results and a combination of these mechanisms [1, 3, 4, 5, 
8, 9, 12, 13]. The risk of second primaries also depends on 
patient age and the amount of time elapsed since anticancer 
therapy [3, 4, 14–16]. According to data published by Lee 
et al., the 30-year overall cumulative incidence of second 
malignancies amounts to 5.2% for children (aged ≤ 14 years), 
13.9% for adolescents and young adults (aged 15–39 years) 
and 16.8% for adults (aged ≥ 40 years) [4].
The definition of multiple primary cancers is based 
on the classic criteria of Warren and Gates which include 
1) the site of origin — tumours arise in different organs 
than independent primaries, 2) morphology and histol-
ogy of tumours — each tumour has to be histologically 
distinctive and the possibility of metastasis or recurrence 
must be excluded, and 3) the amount of time elapsed 
since the initial diagnosis [7, 9, 10]. Considering the time 
of occurrence, multiple primary cancers generally fall into 
two categories: 1) synchronous, if the cancers occur at the 
same time or within 2–6 months, and 2) metachronous, 
if the primaries follow in sequence in a interval time in-
terval of more than 2–6 months [1, 5, 9, 10]. It should be 
noted that the time interval distinguishing synchronous 
and metachronous malignancies has not been precisely 
defined in literature. However, a time interval of 6 months 
between the occurrence of two primaries has been ac-
cepted by some authors [1, 9]. Breast cancer is the most 
common cancer in women; in 2012 it was diagnosed in 1.7 
million women in the world, and in 17 thousand women in 
Poland [17, 18]. In these patients, continuously improving 
survival rates have been observed and, therefore, after 
effective therapy, the majority of them become long-
term survivors with elevated risk of occurrence of second 
malignancies [16, 19, 20–22]. 
The risk of developing multiple primary malignancies 
in breast cancer survivors is increased in the case of posi-
tive family history, the presence of a mutation in tumour 
suppressor genes (BRCA1, BRCA2, PTEN, TP53) as well as in 
survivors with negative family history. Other factors which 
potentially can influence the risk of second malignancy 
include age, body weight, alcohol intake, hormonal replace-
ment therapy and breast cancer therapy [15, 20, 22–24].
According to Lee et al., 10.5% of breast cancer patients 
had multiple primary cancers, of which 23.8% had synchro-
nous, 79% had metachronous and the remaining 2.8% had 
both synchronous and metachronous malignancies [9]. In 
patients with an initial diagnosis of breast cancer, elevated 
risk is observed especially in the development of contralat-
eral breast cancer, endometrial cancer, esophageal cancer, 
ovarian cancer and thyroid cancer [7].
The purpose of this study was 1) to present the char-
acteristics of breast cancer patients with metachronous 
primary malignancies, 2) to compare the characteristics 
in relation to the type of metachronous primaries (breast 
versus non-breast) and 3) to analyse the impact of the type 
of metachronous cancers on survival rate.
Material and methods
Patients
Between 1963 and 2010, 17,066 patients with breast can-
cer were treated at Maria Skłodowska-Curie Memorial Cancer 
Centre and Institute of Oncology in Krakow. Of these, 354 pa-
tients (2.1%) developed metachronous primary malignancies 
and they made up 13.8% of all patients with multiple primary 
cancers. The mean age at diagnosis of the first breast cancer 
was 53 ± 11.5 years (range: 26–83, median: 51 years). Posi-
tive caner family history was noted in 127 patients (35.9%). 
Metachronous contralateral breast cancer appeared in 50 
patients with breast cancer positive family history, comprising 
14.1% of all patients and 39.4% of patients with positive family 
history. Benign breast diseases and/or hormonal disturbances 
were found in 33 individuals (9.3%). 
The clinicopathological characteristics of 354 patients 
with first breast cancer and metachronous primary malig-
nancies are presented in Table I.
The majority of these patients (75.2%) had an early 
stage (pT1–2) of the disease at the time of diagnosis of first 
breast cancer; however, in 52.5% of patients the axillary 
lymph node metastases were confirmed in pathological 
examination. 
Because patients with first breast cancer and me-
tachronous cancers were managed over a period of 47 
years, the diagnostic methods and the spectra of treat-
ment changed along with the indications. Nevertheless, 
surgery was the primary treatment modality in all pre-
sented patients; radical mastectomy was performed in 
337 cases (95.2%), whereas 17 patients (4.8%) underwent 
16
breast-conserving surgery. The following adjuvant therapy 
was applied: postoperative radiotherapy (113 patients 
— 31.9%), chemotherapy (137 patients — 38.7%) and 
hormonotherapy (140 patients — 39.5%), which in 127 
patients (35.8%) was combined with tamoxifen. In some 
cases, multimodal treatment was performed in an adju-
vant setting.
Metachronous primary malignancies  
after breast cancer
In this article, metachronous malignancies are defined 
as primaries following the diagnosis of breast cancer in 
a time interval greater than or equal to 6 months. 
The mean time interval between the diagnosis of breast 
cancer and the appearance of metachronous malignancies 
was 100.9 ± 74.9 months (range: 6–543 months, median: 83 
months). In most patients (220 of 354 — 62.1%) metachro-
nous malignancies developed later than 60 months after 
the initial diagnosis of breast cancer.
In 354 patients treated primarily for breast cancer, 380 
cases of metachronous carcinomas were noted, including 
354 cases of second cancer and, additionally, 24 cases of 
third cancer and 2 cases of fourth cancer. 
The types of all 380 metachronous malignancies are 
presented in Table II. 
The most frequent metachronous malignancy was 
breast cancer (194 cases — 54.8%), which occurred as sec-
ond (192 cases) or third (2 cases) cancer. 
Statistical methods
In the studied population, two groups were distin-
guished: patients with metachronous contralateral breast 
cancer (all patients who developed breast cancer as me-
tachronous primary morbidity) and patients with metachro-
nous non-breast cancer. 
Table I. Characteristics of 354 patients with breast cancer who developed metachronous primary cancers
Parameters (at diagnosis of first breast cancer) No. of patients %
Age (years) 164 46.3
≤ 50 190 53.7
> 50
Menopausal status
Premenopausal 213 60.2
Postmenopausal 141 39.8
Family history (positive) 127 35.9
Breast cancer 38 10.7
Breast cancer and other cancers 12 3.4
Other cancers 77 21.8
Breast disease and other symptoms 33 9.3
Benign breast diseases (fibrocystic changes, hyperplasia) 14 4.0
Hormonal disturbances (hormone replacement therapy, pregnancy-related breast cancer, adnexitis) 17 4.8
BRCA1 or BRCA2 mutation 2 0.6
Histological type
Ductal 298 84.1
Lobular 15 4.2
Othera 41 11.6
Stage of breast cancer
pT 1 77 21.8
pT 2 189 53.4
pT 3 43 12.1
pT 4 35 10.0
pT xb 10 2.8
pN 0 167 47.2
pN+ 186 52.5
pN xb 1 0.3
aOther types of first breast cancer: medullary (12 pts.), mucinous (9 pts.), metaplastic (9 pts.), apocrine (3 pts.), tubular (3 pts.), inflammatory (2 pts.), Paget’s disease of the 
nipple (2 pts.), papillary (pt.); bunknown
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The Pearson’s Chi-square test for independence (for 
categorized variables) and variance analysis with Student’s 
t-test (for continuous variables) were used for comparison 
of the two groups to assess the relation to the frequency of 
the factors analysed.The survival rate (overall and without 
metachronous maligancies) was evaluated with the Kaplan- 
-Meier method, and the log rank test was applied to assess 
the influence of some factors on the evaluated results.
All calculations were performed by STATISTICA v.12 soft-
ware (StatSoft, Inc. Tulsa, OK, USA) and the significance level 
at a = 0.05 was adopted for all statistical analyses. 
Results
The probability of occurrence of new cancer averaged 
from 38.1% to 67.8% for 5 and 10 years after diagnosis of 
first breast cancer, respectively. 
Figure 1 shows the probability of appearance of me-
tachronous primaries in relation to their type (breast or 
non-breast). Lower tendency for the probability of the oc-
currence of the second breast cancer (or metachronous 
contralateral breast cancer) in comparison to the appear-
ance of other types of metachronous primaries was noted 
(36.5% vs 40.1% for 5 years and 64.1% vs 72.2% for 10 years; 
p = 0.05504, log rank test).
Table III presents the results of the comparison of pa-
tients characteristics in relation to the type of metachronous 
malignancy: breast versus non-breast cancers.
Performed analysis showed statistically significant differ-
ences between these groups in relation to age, menopausal 
status, histological type of first breast cancer and implemen-
tation of tamoxifen. Patients who developed metachronous 
contralateral breast cancer, in comparison to patients with 
metachronous non-breast cancers, were significantly young-
er (mean age 50.9 vs 55.5 years; p = 0.00018). The most of 
them were younger than 50 years of age (56.2% vs 34.4%; 
p = 0.00005), in premenopause (69.6% vs 48.8%; p = 0.00007), 
had lobular type of first breast cancer (6.7% vs 1.3%; 
p = 0.04031) and did not use tamoxifen in adjuvant therapy 
for first breast cancer (74.7% vs 51.3%; p < 0.00001). Moreo-
ver, patients with lobular type of first breast cancer more 
frequently developed metachronous contralateral breast 
cancer than other type of metachronous malignancies 
(13 patients — 86.7% vs 2 patients — 13.3%; p = 0.04031). 
Additionally, it was noted that the type of metachronous 
Table II. The types of 380 metachronous primary cancers, which developed in 354 patients after treatment for first breast cancer
Diagnosis of metachronous cancers No. of all cases % Metachronous primaries developed as morbidity:
2nd 3rd 4th
Total 380 100.0 354 24 2
Breast cancer (in contralateral breast) 194 51.1 192 2 -
Female genital organ cancers: 83 21.8 73 10 -
Endometrial cancer 30 7.9 29 1 -
Ovarian cancer 29 7.6 23 6 -
Cervical uteri cancer 21 5.5 19 2 -
Vaginal cancer 2 0.5 1 1 -
Vulvar cancer 1 0.3 1 - -
Digestive organ cancers: 24 6.3 22 2 -
Oesophageal and stomach cancer 8 2.1 7 1 -
Colon cancer 6 1.6 5 1 -
Rectal cancer 6 1.6 6 - -
Biliary tract and pancreatic cancer 4 1.1 4 - -
Skin neoplasms: 21 5.5 18 2 1
Melanoma 10 2.6 9 1 -
Carcinoma 11 2.9 9 1 1
Lung cancer 16 4.2 10 5 1
Urinary tract cancers: 13 3.4 11 2 -
Kidney cancer 9 2.4 7 2 -
Bladder cancer 4 1.1 4 - -
Thyroid cancer 9 2.4 9 - -
Lymphatic tissue neoplasms 9 2.4 8 1 -
Head and neck, eye and brain cancers 7 1.8 7 - -
Soft tissue and bone sarcomas 4 1.1 4 - -
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cancer (breast or non-breast) had significant influence on 
survival (Fig. 2).
The estimated 5-year and 10-year overall survival rates 
were: 92.9% and 80.1%, respectively (for metachronous 
contralateral breast cancer) and 91.3% and 67.8%, respec-
tively (for metachronous non-breast cancer); p = 0.02710, 
log rank test.
The follow-up period since the diagnosis of first breast 
cancer ranged from 7 to 558 months with mean value: 180 ± 
108.7 months and median: 168.5 months. During this period 
195 patients (55.1%) died and the causes of death were as 
following: second cancer (106 cases), third cancer (6 cases), 
coexistent non-cancer internal diseases (50 patients), and 
unknown (33 patients). 
The estimated 5- and 10-year overall survival rates were: 
91.8% and 74.5%, respectively (Fig. 3).
The clinical observation showed that 71 patients (20.1%) 
developed distant metastases in mean period of 28 ± 27.3 
months (range: 1–136 months, median: 18 months). The 
localisations of this failure were as following: bones (28 
cases), liver (12 cases), brain (11 cases), lungs (11 cases), 
distant lymph nodes (11 cases), skin (5 cases), pleura 
(1 case), peritoneum (1 case).
Furthermore, local/regional recurrence of breast cancer 
was noted in 59 patients (16.7%). In 31 patients (8.8%) 
this failure concerned the first breast cancer and it oc-
curred in mean period of 50.2 ± 50.2 months (range: 2–234 
months, median: 36 months). In remaining 28 patients 
(7.9%) recurrence of second breast cancer was observed 
and it developed between 3 and 97 months (mean: 26.8 
± 22.1, median: 19.0 months) after diagnosis of second 
breast cancer.
Discussion
Published data indicate that women with breast cancer 
have an increased risk of developing second primaries. The 
results of meta-analysis performed by Molina-Montes et al. 
indicate that the risk of second cancer in breast cancer pa-
tients is increased by 17% in comparison with the general 
population, and this risk is relative to age at diagnosis of 
the first breast cancer and the time interval between the 
occurrence of the first and second malignancies. Women 
younger than 50 years have a 51% increase in risk in com-
parison to an 11% increase in women aged over 50 years. 
Furthermore, the risk of second malignancy after breast 
cancer is increased by 19% within the first 10 years and 
by 26% after 10 years [15]. 
Published data indicate that age as well as menopausal 
status at diagnosis of breast cancer are important predic-
tors of second primaries [16, 24–34]. Langballe et al., who 
investigated the risk of second malignancies in relation to 
menopausal status in women with breast cancer, noted 
that premenopausal women had an 18% increase in risk 
of appearance of second malignancy and this increased 
risk was confined to endometrial and ovarian cancers. 
Moreover, in postmenopausal women the risk of cervical 
cancer was significantly reduced. The authors speculated 
that these observations resulted from intensified screening 
in comparison to the general population, and are related 
to different lifestyle factors and socioeconomic status [25].
Figure 1. The probability of metachronous primary cancers in relation to the type of metachronous primaries: breast vs non-breast cancer
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In the studied group, 60.2% of women (213 of 354) 
were premenopausal at diagnosis of breast cancer, while 
46.3% (164 of 354) were younger than 50 years of age. The 
comparison of characteristics of patients with metachro-
nous breast vs non-breast malignancies showed significant 
differences in age and menopausal status. Younger age 
(< 50 years) and premenopausal status were significantly 
more frequently observed in patients with matachronous 
contralateral breast cancer (56.2% and 69.9%, respectively) 
in comparison to other types of metachronous malignan-
cies (34.4% and 48.8%, respectively). Another significant 
difference was observed in tamoxifen intake; patients with 
metachronous contralateral breast cancer more frequently 
did not receive tamoxifen (74.7%) in comparison to 51.1% 
Table III. The comparison of patient characteristics in relation to the type of metachronous primary cancers: breast cancer vs non-breast cancer 
Parameters (at diagnosis of first breast cancer) Metachronous primaries
breast
n = 194 (100%)
non-breast
n = 160 (100%)
p
Age (years): 
Mean value 50.9 55.5 0.00018a
≤ 50 109 (56.2%) 55 (34.4%) 0.00005
> 50 85 (43.8%) 105 (65.6%)
Menopausal status:
Premenopausal 135 (69.6%) 78 (48.8%) 0.00007
Postmenopausal 59 (30.4%) 82 (51.3%)
Family history of cancers:
Negative 130 (67%) 97 (60.6%)
Breast cancers 30 (15.5%) 20 (12.5%) 0.09894
Other cancers 34 (17.5%) 43 (26.9%)
Breast disease and other symptoms:
None 145 (90.6%) 176 (90.7%)
Benign breast disease 4 (2.5%) 10 (5.2%)
Hormonal disturbances 10 (6.3%) 7 (3.6%) 0.41446
BRCA1 or BRCA2 mutation 1 (0.6%) 1 (0.5%)
Histological type:
Ductal 159 (82%) 139 (86.9%)
Lobular 13 (6.7%) 2 (1.3%) 0.04031
Other 22 (11.3%) 19 (11.9%)
Stage of first breast cancer:
pT1-2 143 (73.7%) 123 (76.9%) 0.83108
pT3-4 43 (22.2%) 35 (21.9%)
pN0 88 (45.4%) 79 (49.4%) 0.47897
pN+ 105 (54.1%) 81 (50.6%)
Treatment methods:
Radiotherapy          No 127 (65.5%) 114 (71.3%) 0.24513
                                    Yes 67 (34.5%) 46 (28.8%)
Chemotherapy       No 111 (57.2%) 106 (66.3%) 0.08244
                                    Yes 83 (42.8%) 54 (33.8%)
Tamoxifen                No 145 (74.7%) 82 (51.3%) < 0.00001
                                    Yes 49 (25.3%) 78 (48.8%)
Time interval between diagnosis of first breast cancer and metachronous primary cancer (monthsb):
Mean value  108 92.5 0.06533a
≤ 60  69 (35.6%) 65 (40.6%) 0.32881
> 60 125 (64.4%) 95 (59.4%)
ap value from Student’s t-test, other p for chi-square test, bmonths after diagnosis of first breast cancer
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who developed other types of metachronous malignan-
cies. It is important to note that analysed patients were 
managed over the period of 47 years (breast cancers di-
agnosed between 1963 and 2010), and in this time inter-
val the diagnostic methods and the spectra of treatment 
changed along with the indications, e.g. application of 
tamoxifen.
It is known that the elevated risk of subsequent can-
cer which developed in breast cancer survivors is related 
to hormonal (estrogen and progesteron) receptor status 
[26, 35].
Estrogen receptor-negative breast cancer is related to 
an increased risk of subsequent lung cancer. Schonfeld et 
al. presented that the lung cancer rate was significantly el-
evated after treatment of estrogen receptor-negative breast 
cancer. These authors showed a 22% increase in the risk 
of lung cancer in estrogen receptor-negative vs estrogen 
receptor-positive breast cancer patients [35]. It is important 
to mention that estrogen receptor-negative tumours are 
more frequent in younger patients with breast cancer.
In patients with expression of estrogen/progesterone 
receptors (ER/PR), the risk of second malignancy is as-
Figure 3. The probability of overall survival in patients with metachronous primaries developed after first breast cancer
Figure 2. The probability of overall survival according to the type of metachronous primary cancer: breast vs non-breast cancer
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sociated with hormonal therapy (especially tamoxifen). 
Tamoxifen is used for treatment of ER/PR-positive breast 
cancers and for primary breast cancer prevention. How-
ever, this drug may increase the risk of other primary ma-
lignancies [26, 36–38]. Endometrium and gastrointestinal 
organs (colorectum, stomach and liver) may be target 
sites for tamoxifen-induced carcinogenesis [36]. The risk of 
endometrial cancer increases with the time of tamoxifen 
usage; the relative risk rises from 2.0 for 2–5 years to 6.9 
for at least 5 years, p < 0.001 [37]. Additionally, tamoxifen 
users have a worse prognosis of endometrial cancer due 
to less favourable histology and a higher stage of disease. 
The above-mentioned hormonotherapy as well as cy-
totoxic and radiation therapy used in breast cancer patients 
can increase the risk of occurrence of second malignancies 
[3, 4, 6, 20, 22, 24, 26, 36, 37, 39–46].
The results of the Danish national population-based 
study published by Grantzau et al. showed that radiother-
apy-treated early breast cancer patients have a small but 
significantly elevated risk of second cancers [46]. The hazard 
ratio is 1.34 for radiotherapy-associated sites (lung cancer, 
esophageal cancer, soft tissue sarcoma) and for the time 
period of 10–14 years (HR = 1.55) and over 15 years after 
therapy (HR = 1.79)]. The results of Dutch Population-Based 
Study presented by Schaapveld et al., however, showed 
that in patients with breast cancer the 10-year cumula-
tive incidence of second non-breast cancer was 5.4% [24]. 
Among patients younger than 50 years, radiotherapy was 
associated with increased lung cancer risk (HR = 2.31), while 
chemotherapy — with decreased risk of all second non-
breast cancers (HR = 0.78). In patients aged 50 years and 
older, radiotherapy was associated with elevated risk of soft 
tissue sarcomas (HR = 3.43), while chemotherapy — with in-
creased risk of melanoma, uterine cancer and acute myeloid 
leukemia. However, hormonal therapy was associated with 
elevated risk of all second non-breast cancers (HR = 1.1) and 
it especially raised the risk of uterine cancer (HR = 1.78) [24].
The most common second primary cancer in patients 
with breast cancer is contralateral breast cancer, which 
accounts for approximately 50% of all second cancers and 
4.2% of all breast cancers [47]. Breast cancer patients have 
an increased risk (2–6 times) of occurrence of contralateral 
breast cancer, which occurs as metachronous malignancy 
at a rate of 0.13% per year and significantly more frequently 
in lower stages of disease [48].
In the presented group of metachronous malignancies, 
contralateral breast cancer comprised 54.8% (194 cases) 
of all second cancers. 
The risk of contralateral breast cancer is increased with 
positive family history, early age and stage IIB at diagnosis 
first breast cancer, estrogen/progesterone receptor-neg-
ative breast cancer, and lobular histology. Chemotherapy 
and tamoxifen reduce this risk, but the data concerning 
the role of radiotherapy as well as reproductive, environ-
mental and other factors are inconsistent [27, 28, 30, 31, 
32, 45, 49–52]. 
The possible impact of radiotherapy on development 
of contralateral breast cancer after treatment of first breast 
cancer remains undefined. Some authors showed the re-
lationship between high dose volume and second cancer 
sites (lung, esophagus, pleura, bone, soft tissues, contralat-
eral breast) but these risks decreased with increasing age 
and amount of time elapsed since treatment [20, 22, 45]. 
On the other hand, technological development in radio-
therapy and the use of techniques with minimized scat-
tered radiation can reduce this risk and, therefore, the 
frequency of cancers developed in high dose volume are 
strongly associated with environmental and lifestyle fac-
tors, and other therapeutic methods can influence this 
frequency [29, 50]. Lobular type of breast cancer is posi-
tively (over 2 times) associated with the development of 
a contralateral breast cancer [32, 33, 34, 53]. In our group, 
metachronous contralateral breast cancer developed in 
13 of 15 (86.7%) patients with lobular first breast cancer.
The advances and effectiveness of breast cancer ther-
apy resulted in the improvement of the survival rate. El-
evated risk of occurrence of second malignancies in breast 
cancer survivors makes early detection of metachronous 
malignancies obligatory. These patients should be placed 
under much closer post-treatment surveillance in regard 
to screening procedures (e.g. mammography, breast MRI, 
colonoscopy, abdominal and transvaginal ultrasonogra-
phy). Because of the clinical and physiological importance 
of this problem, early detection of second and higher-order 
primary malignancies is an important factor which influ-
ences the quality of life in breast cancer survivors.
Conclusions
1.  The most frequent type of metachronous malignancy 
in patients with breast cancer is contralateral breast 
cancer (54.8% cases).
2.  Patients with contralateral breast cancer in comparison 
to other types of metachronous malignancies were 
younger (under 50 years) and premenopausal, had 
lobular type of first breast cancer and rarely received 
tamoxifen (25.3% vs 48.2%). They had a significantly 
better prognosis than patients with other types of 
metachronous malignancies (10-year overall survival 
rates were 80.1% vs 67.8%, p = 0.0271).
3.  The breast cancer survivors have an indication for 
some screening procedures, because the early detec-
tion of second and higher-order primary malignancies 
is an important factor which influences the quality of 
life in breast cancer survivors.
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